Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Why Novartis rebranded to tell patients, ‘We’re with you’
Medical Marketing and Media
Fri, 01/5/24 - 09:53 am
Tags:
Novartis, rebranding
Novartis, Voyager launch another gene therapy mission with $100M upfront deal
Fierce Biotech
Tue, 01/2/24 - 10:05 am
Tags:
Novartis, gene therapy, Voyager Therapeutics, Huntington's disease, SMA
Roche, Novartis move Xolair closer to FDA finish line for food allergies
Fierce Pharma
Tue, 12/19/23 - 11:10 pm
Tags:
Roche, FDA, Xolair, food allergies, Novartis
Novartis unveils promising Fabhalta data for C3 glomerulopathy indication
Medical Marketing and Media
Tue, 12/12/23 - 09:56 am
Tags:
Novartis, clinical trials, Fabhalta, iptacopan, C3 glomerulopathy
Novartis gears up for label expansion for Kisqali with Phase III results
Clinical Trials Arena
Mon, 12/11/23 - 11:18 am
Tags:
Novartis, Kisqali, FDA, clinical trials, early breast cancer, breast cancer
ASH: As Novartis enters PNH market, AstraZeneca shows longer term effect of its latest contender
Fierce Biotech
Mon, 12/11/23 - 10:07 am
Tags:
ASH 2023, AstraZeneca, Novartis, PNH, danicopan
Novartis hit with FDA letter detailing 'significant' Kymriah manufacturing shortfalls
Fierce Pharma
Thu, 12/7/23 - 10:08 am
Tags:
Novartis, FDA, Kymriah, CAR-T, drug manufacturing
Daiichi Sankyo unit claims $182m in Novartis patent dispute
Pharmaphorum
Wed, 12/6/23 - 10:31 am
Tags:
Daiichi Sankyo, Novartis, Plexxikon, legal, patents, Tafinlar
Novartis receives FDA approval for Fabhalta to treat PNH in adults
Pharmaceutical Business Review
Wed, 12/6/23 - 10:25 am
Tags:
Novartis, FDA, Fabhalta, iptacopan, PNH, paroxysmal nocturnal hemoglobinuria
Novartis sees brighter sales future as R&D revamp continues
BioPharma Dive
Tue, 11/28/23 - 11:36 pm
Tags:
Novartis, R&D
Novartis pays Legend $100M upfront to give solid tumor CAR-T the T-Charge treatment
Fierce Biotech
Mon, 11/13/23 - 11:55 am
Tags:
Novartis, Legend Biotech, CAR-T, T-Charge, solid tumors
Novartis’ urticaria drug meets all endpoints in Phase III trials
Clinical Trials Arena
Fri, 11/10/23 - 10:05 am
Tags:
Novartis, remibrutinib, chronic spontaneous urticaria, clinical trials
Novartis Inks Potential $1.3B Contract with Korean Biotech for Small Molecule
BioSpace
Tue, 11/7/23 - 10:05 am
Tags:
Novartis, Chong Kun Dang Pharmaceutical, small molecule drugs
FDA approves Novartis Cosentyx as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
Yahoo Finance
Wed, 11/1/23 - 10:14 pm
Tags:
Novartis, Cosentyx, FDA, hidrad
Atrasentan data backs up Novartis’ $3.5bn Chinook deal
Pharmaphorum
Mon, 10/30/23 - 10:21 am
Tags:
Novartis, IgA nephropathy, atrasentan, Chinook Therapeutics
Tricks and Treats as Biopharma’s Q3 Earnings Season Gets Underway
BioSpace
Sun, 10/29/23 - 08:53 pm
Tags:
earnings, Bristol Myers Squibb, Takeda, Novartis, Sanofi, Merck
Novartis claims ex-staffer jumped to Takeda with 'thousands' of sensitive files
Fierce Pharma
Thu, 10/26/23 - 10:52 pm
Tags:
Novartis, Takeda, trade secrets
Novartis Beats Earnings Estimate in Q3, Raises Full-Year Guidance
BioSpace
Tue, 10/24/23 - 07:46 pm
Tags:
Novartis, earnings
Novartis Builds Case for Earlier Prostate Cancer Treatment with Phase III Data
BioSpace
Tue, 10/24/23 - 09:54 am
Tags:
ESMO, Novartis, prostate cancer, Pluvicto, radiopharmaceuticals
Novartis expats detail their health-tech spinoff DatosX
Medical Marketing and Media
Wed, 10/11/23 - 11:44 pm
Tags:
Novartis, innovation, digital health, spinoffs, DatosX

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.